OVERVIEW
Welcome to the Direct-to-Consumer Working Group
As the life sciences industry rapidly expands into direct‑to‑consumer models, the need for uncompromising product quality, patient safety, and supply chain transparency has never been greater. The Rx‑360 Direct‑to‑Consumer Working Group brings together global leaders across pharma, biotech, medical device, logistics, and digital health to address the unique challenges and opportunities of this evolving landscape.
Inquire About the Direct-to-Consumer Working Group
Direct-to-Patient Pharmaceutical Programs
The pharmaceutical landscape is evolving rapidly, and one of the most transformative shifts is the rise of direct-to-patient (D2P) distribution. As manufacturers seek to bypass traditional channels and deliver medications straight to patients’ doors, the […]
The BIOSECURE Act and the Quiet Work Ahead for Pharmaceutical Supply Chains
The BIOSECURE Act did not arrive with ceremony. It arrived embedded in the National Defense Authorization Act, debated largely in abstractions, and passed with little public attention. But for pharmaceutical and biotechnology companies operating global […]